STAT+

Health tech Mohana Ravindranath

STAT Plus: Federal judge rules in favor of hospital lobby in privacy lawsuit

Biotech Jason Mast and Matthew Herper

STAT Plus: Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Ginkgo Bioworks lays off 158 employees, with more to come

Biotech Jason Mast

STAT Plus: FDA approves Sarepta’s Duchenne gene therapy for nearly all patients

Pharmalot Ed Silverman

STAT Plus: Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments

In the Lab Angus Chen

STAT Plus: New immunotherapy combination could ‘change the landscape’ of cancer treatment

Biotech Elaine Chen

STAT Plus: Zealand’s amylin-targeting drug shows early potential in obesity

Exclusive Ed Silverman

STAT Plus: Doctors Without Borders is closing its widely regarded access-to-medicines campaign

Biotech Jason Mast

STAT Plus: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals

Health Nicholas St. Fleur

STAT Plus: Q&A: Bold’s CEO on fall prevention, ageism in health care, and ‘movement is medicine’

Health Jonathan Wosen

STAT Plus: New study bolsters evidence rare genetic mutation can delay early Alzheimer’s

Business Bob Herman

STAT Plus: Novant Health calls off North Carolina hospital deal, giving a win to the FTC

Exclusive Casey Ross

STAT Plus: Republican lawmakers criticize FDA’s partnership with CHAI on regulating AI in medicine

Health tech Lizzy Lawrence

STAT Plus: Boston Scientific to buy vascular device maker for $1.16 billion

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more

Biotech Matthew Herper

STAT Plus: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease

Health tech Mario Aguilar

STAT Plus: Freespira bets on slow and steady, amid spectacular digital health collapses

Health tech Brittany Trang

STAT Plus: To feed an AI that designs new enzymes, Basecamp Research hunts rare proteins at the world’s end

Health Care Inc. Bob Herman

STAT Plus: Why health care spending keeps climbing

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an ‘unaffordable’ Novartis drug, a proposed patent rule, and more

Pharmalot Ed Silverman

STAT Plus: Under pressure to thwart pharma patent abuse, the PTO proposes a new rule. But will it fly?

Business Bob Herman

STAT Plus: Why a big California employer ditched Elevance for some of its health plans

Health Angus Chen

STAT Plus: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data

Pharmalot Ed Silverman

STAT Plus: Colorado board decides a pricey Novartis medicine is unaffordable

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Business Bob Herman

STAT Plus: Biden administration to recalculate Medicare Advantage quality ratings and bonuses

Biotech Meghana Keshavan

STAT Plus: FDA gets pointed input on ‘optimizing’ advisory committee panels

Business Mohana Ravindranath and Katie Palmer

STAT Plus: Telehealth startup Done’s top leadership arrested on fraud charges